Program
KN057
A development code. Also written as “KN057 doseⅠ”, “KN057 dose Ⅱ” and “KN057 dose Ⅲ”.
Its studies are mostly in Hemophilia A, led by Suzhou Alphamab.
Furthest: phase 3, since Dec 30, 20235 company-led studies, 4 open or runningNext primary completion: Dec 30, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Alphamab | 54 open or running | phase 3since Dec 30, 2023 | Jun 9, 2022 | Dec 30, 2027phase 3 · NCT07545395 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 9, 2022First study: phase 2 study in Hemophilia AFirst studyNCT05421429 · 24 enrolled · China
- Dec 30, 20232 phase 3 studiesNCT06569108, NCT06312475
- Dec 11, 2024Phase 2 study in Hemophilia ANCT06747416 · 24 planned
- Mar 8, 2026Phase 3 study in Hemophilia ANCT07545395 · 70 planned · China
Ahead
- Dec 30, 2027Primary completion: phase 3 study in Hemophilia ANCT07545395
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07545395Hemophilia A · China | 3 | Recruiting | Dec 30, 2027 | 70 |
| NCT06747416Hemophilia A | 2 | Not yet recruiting | Sep 2, 2026 | 24 |
| NCT06569108Hemophilia A Without Inhibitor · China | 3 | Active, not recruiting | Oct 15, 2026 | 125 |
| NCT06312475Hemophilia A With Inhibitor · China | 3 | Active, not recruiting | Oct 15, 2025 | 53 |
| NCT05421429Hemophilia A · China | 2 | Completed | Jan 17, 2024 | 24 |
How it is read
Names in the registry
- “KN057”, 4 entries
- “KN057 doseⅠ”, 1 entry
- “KN057 dose Ⅱ”, 1 entry
- “KN057 dose Ⅲ”, 1 entry
Codes read as this program: KN057.
Conditions, from the studies’ own filings
- Hemophilia A, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.